Prostate Cancer Incidence Remains High Among Older Men
According to the American Cancer Society, one in eight men will be diagnosed with prostate cancer during their lifetime. Six out of every ten cases occur in men over 65 years of age, with a median age of diagnosis at 67 years. Prostate cancer is rare in men under 40 years of age. Notably, the risk is significantly higher among African American men and Caribbean men of African ancestry.2
"Our aim with the AMPLITUDE study was to determine how long patients could live without their cancer worsening. What we found is that the combination of niraparib, abiraterone acetate, and prednisone is achieving just that, with the goal of offering patients precious quality time before the disease enters a more resistant phase," said Charles Drake, MD, PhD, FAAP, VP, prostate cancer and immunotherapy disease area leader, Johnson & Johnson Innovative Medicine, in the press release. "This breakthrough highlights the need for early initiation of personalized treatment strategies for patients with mCSPC and HRR alterations, particularly BRCA, who typically face more aggressive disease."
References
1. Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC. PR Newswire. June 3, 2025. Accessed June 4, 2025. https://prnmedia.prnewswire.com/news-releases/johnson--johnson-leads-with-first-parp-inhibitor-combo-to-improve-efficacy-in-patients-with-hrr-altered-mcspc-302471320.html
2. Key Statistics for Prostate Cancer. American Cancer Society. Accessed June 4, 2025. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html